Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.2M Buy
15,136
+64
+0.4% +$8.84K 0.42% 43
2026
Q2
$1.94M Buy
15,072
+252
+2% +$29.5K 0.34% 59
2026
Q1
$1.78M Buy
14,820
+702
+5% +$81K 0.4% 56
2025
Q4
$1.49M Buy
14,118
+539
+4% +$50.6K 0.35% 64
2025
Q3
$1.14M Buy
13,579
+2,822
+26% +$232K 0.28% 80
2025
Q2
$852K Sell
10,757
-481
-4% -$38.2K 0.24% 90
2025
Q1
$1.01M Sell
11,238
-59
-0.5% -$5.51K 0.34% 68
2024
Q4
$1.28M Hold
11,297
– – 0.42% 54
2024
Q3
$1.28M Buy
11,297
+283
+3% +$33.6K 0.42% 55
2024
Q2
$1.36M Sell
11,014
-7
-0.1% -$902 0.47% 47
2024
Q1
$1.45M Sell
11,021
-311
-3% -$38.3K 0.53% 42
2023
Q4
$1.24M Buy
11,332
+125
+1% +$13K 0.52% 44
2023
Q3
$1.15M Hold
11,207
– – 0.55% 49
2023
Q2
$1.29M Sell
11,207
-20
-0.2% -$2.27K 0.61% 40
2023
Q1
$1.19M Buy
11,227
+75
+0.7% +$8.1K 0.62% 39
2022
Q4
$1.24M Buy
+11,152
New +$1.14M 0.72% 34

Other funds holding MRK

Chapin Davis's MRK Position: Q3 2026 in Review

Chapin Davis increased its Merck (MRK) stake by 0.42% in Q3 2026, buying an estimated $8.84K and bringing the position to 15,136 shares worth $2.2M. The position accounts for 0.42% of the portfolio, ranked #43.

Chapin Davis first reported a position in MRK in Q4 2022 and has held it in 16 quarters since. 477 funds tracked by Wall St. Rank hold MRK as of Q3 2026.

  • Chapin Davis held 15,136 shares of Merck worth $2.2M as of Q3 2026.
  • Chapin Davis bought 64 Merck shares in Q3 2026, an estimated $8.84K.
  • Merck made up 0.42% of Chapin Davis's portfolio in Q3 2026, its #43 holding.
  • Chapin Davis first reported a position in Merck in Q4 2022 and has held it in 16 quarters since.
  • 477 funds tracked by Wall St. Rank held Merck as of Q3 2026.

Based on Chapin Davis's 13F filing for Q3 2026, filed 9 Oct 2026.